Key Metrics of Jubilant Pharmova Limited
About Jubilant Pharmova Limited
Sectors
Company details
- Registered office
- Bhartiagram Gajraulajyotiba Phoolay Nagar, U P, Uttar Pradesh, India,, Bhartiya Gram, In-up, 244223
- Listed
- NSE: JUBLPHARMA · ₹939.60
Operational Areas of Jubilant Pharmova Limited
Company summary
Entity details
Compliance
Industry classification
Financials, ratios and risk analysis
Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.
Sign in to continue See plans & pricingFiling compliance
Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Credit ratings
Rating history
Rating actions
| Date | Agency | Action | Long term | Short term | Outlook | Rated amount | Rationale |
|---|---|---|---|---|---|---|---|
| 14 Oct 2026 | ICRA | Assigned | AA+ | — | Stable | ₹1,400 Cr | View |
Credit strengths (ICRA, Oct 2026)
+ Diversified revenue profile
The company has a diversified revenue profile comprising radiopharmaceuticals (14% of FY2026 revenues), radiopharmacies (30%), allergy immunotherapy (9%), CDMO for sterile injectables (21%), CRDMO (15%) and generics (9%).
Credit challenges
− Exposed to regulatory risks
Akin to its peers in the pharmaceutical industry, JPM’s operations remain exposed to regulatory risks, including the scrutiny by regulatory agencies like the USFDA and other product liability matters, and any developments in this regard shall be evaluated on a case-to-case basis.
Could lead to an upgrade
The rating can be upgraded in case of significant growth in JPM’s scale and profitability, aided by ramp-up of new capacities/products, increased product diversification and improvement in financial leverage, resulting in sustained improvement in its return indicators and strengthening of its financial risk profile.
Could lead to a downgrade
The rating can be downgraded in case of a sustained increase in JPM’s leverage beyond ICRA’s expectations including on account of higher-than-estimated capex, inorganic investments or any sustained weakening in its revenues and profitability due to lower-than-anticipated scale-up in performance of the key segments. Further, materially adverse regulatory actions or non-compliances relating to its products/manufacturing facilities, thereby impacting ongoing operations or new product launches and, in turn, earnings, would also be a negative trigger.
Agency-reported financials (ICRA, 14 Oct 2026)
| Metric | FY2025 | FY2026 |
|---|---|---|
| Operating income (OI) | ₹7,235 Cr | ₹8,280 Cr |
| PAT | ₹837 Cr | ₹398 Cr |
| OPBDITA/OI | 16.2% | 15.2% |
| PAT/OI | 11.6% | 4.8% |
| Total outside liabilities/Tangible net worth (times) | 1.00× | 1.20× |
| Total debt/OPBDITA (times) | 2.30× | 2.90× |
| Interest coverage (times) | 4.90× | 5.90× |
| Revenue growth (YoY) | — | 14.4% |
| EBITDA (margin × income) | ₹1,172 Cr | ₹1,259 Cr |
| Implied total debt (debt/EBITDA × EBITDA) | ₹2,696 Cr | ₹3,650 Cr |
| Implied interest cost (EBITDA ÷ coverage) | ₹239 Cr | ₹213 Cr |
Borrowings & rated debt
Facility mix
Rated facilities
| Facility | Type | Previous | Current | Change | Rating | Action | Agency |
|---|---|---|---|---|---|---|---|
| Non-convertible debenture programme | Debentures & bonds | — | ₹1,400 Cr | — | AA+ (Stable) | Assigned | ICRA |
Credit assessment · Manufacturing
Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2025-26
Ratios, pillar scores and the indicative rating are part of Premium.
Rating status
| Default | No default on record |
| Issuer cooperation | Cooperating |
| Credit enhancement | None – standalone rating |
| Next action stable or better (model) | 62% |
| Information on file | 78% · missing: Capex / investment plans, Auditor details |
Indicative assessment from public data using the published methodology factors; not a credit rating.
Borrowing & funding lifecycle
- Credit outlook model: 64% chance the next rating action is stable or better
- Current rating AA+ (investment grade)
- Interest coverage 5.9×
Rated limits by facility
Timeline
From the report
Also, JPM’s financial profile draws comfort from its large cash balances and liquid investments of close to Rs. 1,300 crore as on March 31, 2026.
From the report
Government interventions related to price caps/control also remain a key social risk faced by entities in the pharmaceutical industry. www.icra.in Sensitivity Label : Public Page |3 Liquidity position: Adequate JPM’s liquidity is Adequate, aided by healthy cash flow generation from operations as well as cash, cash equivalents and liquid investments of Rs. 1,271.4 crore as on March 31, 2026.
From the report
These shall be sufficient to fund its repayment obligations of around Rs. 124.3 crore in FY2027 and Rs. 167.8 crore in FY2028.
Lender names, bank charges and audited borrowings are part of Premium.
Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.
Registered office and contact
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Jubilant Pharmova Limited
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
 Dr. Reddy's Laboratories |
Part of Dr. Reddy's Laboratories. | drreddys.com | 1984 | India |
 Aurobindo Pharma |
Part of Aurobindo Pharma. | aurobindo.com | 1986 | Hyderabad, India |
 Cipla |
Part of Cipla. | cipla.com | 1935 | Mumbai, India |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lupin.com | 1968 | India | |
 Glenmark Pharmaceuticals |
Part of Glenmark Pharmaceuticals. | glenmarkpharma.com | 1977 | Mumbai, India |
| Part of Biocon. | biocon.com | 1978 | Bangalore, India | |
 Alkem Laboratories Limited |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | alkemlabs.com | 1973 | Mumbai, Maharashtra, India |
 Torrent Pharmaceuticals |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | torrentpharma.com | 1959 | Ahmedabad, India |
| Aster DM Quality Care Limited | Discovered Companies · Other Industries | — | — | Hyderabad, Telangana, India |
 Thomas Cook India |
Part of Thomas Cook Group. | thomascook.in | 1978 | Mumbai, India |
Similar companies
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.